Education
About Us
Working with TipRanks
Follow Us
PaxMedica, Inc. (PXMD)
OTHER OTC:PXMD
PXMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.26
Previous CloseN/A
Volume26.44K
Average Volume (3M)37.62K
Market Cap
$2.18K
Enterprise ValueN/A
Total Cash (Recent Filing)$324.49K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta49.76
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.88
Shares Outstanding10,879,170
10 Day Avg. Volume1,549
30 Day Avg. Volume37,622
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PaxMedica, Inc. News
PXMD FAQ
What was PaxMedica, Inc.’s price range in the past 12 months?
PaxMedica, Inc. lowest stock price was $0.03 and its highest was $0.26 in the past 12 months.
What is PaxMedica, Inc.’s market cap?
PaxMedica, Inc.’s market cap is $2.18K.
When is PaxMedica, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PaxMedica, Inc.’s earnings last quarter?
Currently, no data Available
Is PaxMedica, Inc. overvalued?
According to Wall Street analysts PaxMedica, Inc.’s price is currently Overvalued.
Does PaxMedica, Inc. pay dividends?
PaxMedica, Inc. does not currently pay dividends.
What is PaxMedica, Inc.’s EPS estimate?
PaxMedica, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PaxMedica, Inc. have?
PaxMedica, Inc. has 10,879,170 shares outstanding.
What happened to PaxMedica, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PaxMedica, Inc.?
Currently, no hedge funds are holding shares in PXMD
Company Description
PaxMedica, Inc.
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
PaxMedica, Inc. (PXMD) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Scorpius Holdings
―
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―
Ownership Overview
Options Prices
Currently, No data available
---